← Back to Home

How Does Liver Cancer Activate Cholesterol Production? Study Reveals Another Cancer-Promoting Role for EZH2

EZH2, best known for repressing genes, can also cooperate with a metabolic regulatory protein to drive cholesterol production in cancer cells. Experimental protein-degrading molecules have inhibited tumor growth in preclinical models, but their safety and benefits in humans still need to be verified before they can become treatments.

By SURL BioNews

Liver cancer cells may rely on a cholesterol production mechanism activated by a cancer-associated protein to sustain their growth. Researchers at Duke University School of Medicine found that EZH2 cooperates with SREBP2, which regulates cholesterol synthesis, to activate a series of metabolic genes. Disrupting this partnership slowed tumor growth in preclinical models, offering clues to potential therapeutic targets.

Duke University highlighted the findings on October 29, but the study was not first published that day. According to PubMed records, the paper was published online in *Nature Cell Biology* on August 14, 2026, and included in the October issue. Research records from the Icahn School of Medicine at Mount Sinai also confirm the same peer-reviewed paper, which centers on the link between EZH2, gene regulation, and cancer cell metabolism.

EZH2 is generally regarded as a protein that silences genes and is frequently overexpressed in various cancers, including liver cancer. However, after mapping its activity across the genome of liver cancer cells, the researchers identified another role: it can work with SREBP2 to promote the expression of genes associated with the mevalonate pathway, increasing cholesterol biosynthesis and supporting tumor growth.

The paper also provides a more detailed molecular explanation of this activity. It reports that the transcriptional activation domains of EZH2 and SREBP2 can each bind directly to p300, helping to activate the relevant genes. In other words, EZH2 participates in gene activation here, allowing researchers to understand how it promotes cancer beyond its conventional gene-silencing function.

The team then used EZH2-targeting proteolysis-targeting chimeras, or PROTACs, to test whether this pathway could be disrupted. These experimental molecules prompt cells to clear the target protein. In the study, different EZH2-targeting PROTACs reduced the protein levels of both EZH2 and SREBP2, suppressed the expression of SREBP2-associated genes, and inhibited tumor growth in experimental models.

However, these results currently provide preclinical evidence and cannot yet establish whether patients would benefit from treatment. Which liver cancers depend most heavily on this pathway, whether degrading both proteins would affect normal tissues, and whether suitable drug exposure and a safe dosing range can be achieved are all questions that must be clarified before human trials. The findings on cholesterol production within cells also cannot be directly interpreted as evidence that dietary changes would have the same effect.

According to Duke University, the team will next continue optimizing EZH2-targeting PROTACs to bring them closer to viable drug candidates, then test their effects in preclinical liver cancer models, both alone and in combination with existing anticancer drugs. The significance of the study lies in turning a molecular mechanism into a therapeutic hypothesis that can be tested further.

The paper also discloses that co-author Jian Jin holds equity in Cullgen and has scientific advisory, consulting, or research funding relationships with several biotechnology companies; the other authors declared no competing interests. These commercial relationships are relevant background to consider when evaluating subsequent drug development results.

References

  1. Duke University School of Medicine
  2. PubMed / National Library of Medicine
  3. Icahn School of Medicine at Mount Sinai